Us Oncology Research, Llc
- Type
- Non-covered entity
- Where
- Chicago, IL
- Received
- $12,332,257 in 3,187 records, 2019 to 2025 ($0 general, $12,332,257 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 467 | $860,273 |
| 2024 | Research payment | 673 | $2,570,587 |
| 2023 | Research payment | 793 | $2,473,841 |
| 2022 | Research payment | 709 | $1,941,312 |
| 2021 | Research payment | 135 | $1,361,894 |
| 2020 | Research payment | 198 | $1,461,606 |
| 2019 | Research payment | 212 | $1,662,742 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genentech, Inc. | 925 | $3,475,623 | 2022–2025 |
| Clovis Oncology, Inc. | 350 | $2,535,477 | 2019–2022 |
| Novocure Inc. | 187 | $1,072,741 | 2019–2025 |
| TG Therapeutics, Inc. | 779 | $1,042,001 | 2022–2024 |
| Merck Sharp & Dohme LLC | 9 | $864,093 | 2020–2021 |
| TOLMAR, INC. | 406 | $756,393 | 2023–2025 |
| ADC THERAPEUTICS AMERICA, INC. | 122 | $660,355 | 2022–2024 |
| Blueprint Medicines Corporation | 130 | $562,101 | 2020–2022 |
| Hoffmann-La Roche Limited | 83 | $291,503 | 2023–2025 |
| Celgene Corporation | 22 | $246,976 | 2019 |
| Bayer Healthcare Pharmaceuticals Inc. | 49 | $181,511 | 2022–2023 |
| Immunomedics, Inc. | 32 | $176,030 | 2020 |
| Napo Pharmaceuticals Inc | 39 | $117,886 | 2024 |
| CTI BioPharma Corp. | 11 | $100,280 | 2022–2023 |
| Chugai Pharmaceutical Co., Ltd. | 4 | $82,758 | 2023–2025 |
| BeiGene, Ltd. | 6 | $62,448 | 2024 |
| pharmaand GmbH | 6 | $49,006 | 2023 |
| Sumitomo Pharma America, Inc. | 6 | $19,250 | 2023 |
| SOBI, INC | 3 | $12,306 | 2024 |
| Halozyme Inc | 5 | $8,694 | 2019 |
| Eli Lilly and Company | 2 | $6,781 | 2019–2020 |
| Amgen Inc. | 3 | $5,139 | 2019 |
| Janssen Research & Development, LLC | 7 | $1,672 | 2024–2025 |
| Deciphera Pharmaceuticals Inc. | 1 | $1,225 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,187 | $12,332,257 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-26 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-23 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 | |
| 2025-12-23 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 | |
| 2025-12-23 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 | |
| 2025-12-23 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 | |
| 2025-12-19 | Genentech, Inc. | $23,805 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-19 | Genentech, Inc. | $1,587 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-11 | Genentech, Inc. | $3,218 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-12-04 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-26 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-21 | TOLMAR, INC. | $9,500 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-21 | TOLMAR, INC. | $3,532 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-11-21 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-21 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-21 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-21 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-21 | TOLMAR, INC. | $889 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-11-21 | TOLMAR, INC. | $153 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-21 | TOLMAR, INC. | $35 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-11-14 | Genentech, Inc. | $10,000 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-14 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-11-07 | TOLMAR, INC. | $9,500 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-11-07 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-11-07 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-11-07 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-10-29 | Genentech, Inc. | $1,417 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-29 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-10-29 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-10-24 | Chugai Pharmaceutical Co., Ltd. | $2,558 | Research payment | Cash or cash equivalent | A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH | 2025 | |
| 2025-10-22 | Genentech, Inc. | $33,850 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-22 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-17 | TOLMAR, INC. | $3,062 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-10-17 | TOLMAR, INC. | $1,768 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-10-15 | Genentech, Inc. | $10,079 | Research payment | Cash or cash equivalent | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2025 | |
| 2025-10-09 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-09 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-09 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-09 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-09 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-08 | Genentech, Inc. | $1,296 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-03 | TOLMAR, INC. | $9,500 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-10-03 | TOLMAR, INC. | $1,445 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-10-03 | TOLMAR, INC. | $88 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-10-01 | Genentech, Inc. | $2,160 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-01 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-01 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-01 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-10-01 | Genentech, Inc. | $1,296 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-10-01 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $1,417 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $1,417 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $1,417 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-18 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,296 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $1,296 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $864 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $864 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $432 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-12 | Genentech, Inc. | $432 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-10 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | TOLMAR, INC. | $9,500 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-09-03 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $9,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | TOLMAR, INC. | $8,500 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,728 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | Genentech, Inc. | $1,375 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-09-03 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-09-03 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-09-03 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-09-03 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-09-03 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-09-03 | TOLMAR, INC. | $1,200 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-09-03 | TOLMAR, INC. | $153 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-09-03 | TOLMAR, INC. | $35 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-08-26 | Genentech, Inc. | $9,522 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $7,812 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $6,348 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,417 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $290 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $265 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-26 | Genentech, Inc. | $45 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-21 | Genentech, Inc. | $10,000 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-18 | Janssen Research & Development, LLC | $152 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus A | 2025 |
| 2025-08-15 | Genentech, Inc. | $2,882 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-08-15 | Genentech, Inc. | $1,728 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-08-15 | Genentech, Inc. | $1,296 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-08-15 | Genentech, Inc. | $1,154 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | Polarix | 2025 |
| 2025-08-07 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-08-07 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-07-25 | TOLMAR, INC. | $3,032 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-07-25 | TOLMAR, INC. | $3,032 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-07-25 | TOLMAR, INC. | $2,797 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-07-25 | TOLMAR, INC. | $1,504 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-07-25 | TOLMAR, INC. | $1,445 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A | 2025 |
| 2025-07-18 | TOLMAR, INC. | $3,062 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-07-18 | TOLMAR, INC. | $889 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-07-18 | TOLMAR, INC. | $889 | Research payment | Cash or cash equivalent | OVELIA Drug, Endocrinology | TOL2506A-EXT | 2025 |
| 2025-07-17 | Genentech, Inc. | $454 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-07-17 | Genentech, Inc. | $454 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-07-10 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-07-10 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-07-10 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 | |
| 2025-07-10 | Genentech, Inc. | $1,363 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2025 |
The latest 200 records of 3,187.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Chicago, IL, county Cook County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Chicago, IL | County Cook County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 2,711,226 | 5,182,090 | 12,694,798 |
| Population, 2020 census P1 | 2,746,388 | 5,275,541 | 12,812,508 |
| Median age B01002 | 35.8 | 38.0 | 39.0 |
| Under 18 B01001 | 19.4% | 21.1% | 21.8% |
| 65 and over B01001 | 13.8% | 16.0% | 17.0% |
| Households B11001 | 1,160,205 | 2,100,230 | 5,036,449 |
| Foreign born B05002 | 20.9% | 21.7% | 14.7% |
| Median household income B19013 | $77,902 | $83,498 | $83,390 |
| Median family income B19113 | $95,774 | $104,836 | $106,018 |
| Per capita income B19301 | $50,086 | $49,329 | $46,406 |
| Poverty rate B17001 | 16.8% | 13.5% | 11.8% |
| Unemployment rate B23025 | 8.0% | 7.0% | 5.8% |
| Civilian labor force B23025 | 1,517,330 | 2,792,888 | 6,652,134 |
| Mean commute (minutes) B08013 | 33.1 | 31.5 | 27.8 |
| Bachelor's degree or higher B15003 | 44.3% | 42.7% | 37.8% |
| Housing units B25001 | 1,277,054 | 2,276,493 | 5,457,452 |
| Owner-occupied B25003 | 46.0% | 57.7% | 67.1% |
| Renters B25003 | 54.0% | 42.3% | 32.9% |
| Median home value B25077 | $334,100 | $324,500 | $263,300 |
| Median gross rent B25064 | $1,440 | $1,435 | $1,274 |
| White, not Hispanic B03002 | 32.1% | 40.1% | 58.1% |
| Black B03002 | 27.4% | 21.8% | 13.3% |
| Hispanic or Latino B03002 | 29.7% | 26.8% | 18.8% |
| Asian B03002 | 7.2% | 7.9% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chicago, IL.
Comments